Landos Biopharma, Inc. announced that Patrick Truesdell intent to resign as the Company?s Vice President, Controller and Principal Accounting Officer. The Company intends to commence a search for a Chief Financial Officer in the near term. Mr. Truesdell will remain with the Company until November 10, 2023 in order to facilitate the transition.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.38 USD | +0.77% | +0.22% | +509.29% |
Apr. 02 | North American Morning Briefing : Stocks Seen -2- | DJ |
Apr. 01 | HC Wainwright Downgrades Landos Biopharma to Neutral From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+509.29% | 69.41M | |
+25.00% | 46.71B | |
+48.83% | 41.8B | |
-1.04% | 41.52B | |
-5.86% | 29.55B | |
+10.54% | 25.78B | |
-20.38% | 19.26B | |
+2.13% | 12.14B | |
-3.00% | 12.08B | |
+28.20% | 11.98B |
- Stock Market
- Equities
- LABP Stock
- News Landos Biopharma, Inc.
- Landos Biopharma, Inc. Announces Resignation of Patrick Truesdell as Principal Accounting Officer, Patrick Truesdell Remain with Company Until November 10, 2023